Background: Celiac disease (CD) is an inflammatory and immune-mediated gluten-dependent enteropathy occurring in genetically susceptible individuals. CD is recognized to affect between 0.6% and 1% of worldwide population, with wide regional differences. Disease clinical features are protean and highlight the systemic nature of the disease. In recent years, an increased prevalence of CD has been also reported in patients with connective tissue diseases (CTDs). This association may be due to a shared genetic predisposition, to immunological mechanisms and/or exposure to a common triggering event. However, this observation remains controversial since data are usually based on descriptive case reports. Different methods of antibody detection and enrolled population sample size may contribute to result discordance. Moreover, CD diagnosis is often delayed because disease clinical spectrum may be atypical mimicking rheumatologic conditions and autoimmune disease itself may display typical symptoms of CD. Undoubtedly, awareness of CD occurrence in CTDs is important to prevent potential long-term systemic complications related to an unrecognized CD in these patients. Objectives: To evaluate the prevalence of overt and subclinical CD and features of the disease in a large cohort of patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and primary Sjögren's syndrome (pSS) with a multicenter prospective study involving 9 Italian Rheumatology Units. Methods: Data from consecutive 580 SLE, 354 pSS and 524 SSc patients were collected. Disease-specific features were registered in patients with known CD. Remaining patients were tested for IgA transglutaminase (Eu-tTG ® human IgA new, Eurospital S.p.A., Trieste). Anti-endomysium (EMA) IgA and IgG were tested in IgA tTG positive and borderline patients. Esophagogastroduodenoscopy with duodenal biopsy was proposed in IgA tTG+/EMA+, IgA tTG-/EMA+ and IgA tTG±/EMA+ patients. Results: CD prevalence was 1,7% in SLE, 7% in pSS and 1,3% in SSc patients. Higher frequency of elevated liver enzymes was detected in SLE-CD and of herpetiform dermatitis in SSc-CD patients in comparison to the other groups (p<0.05 for both). Interestingly, pSS-CD and SSc-CD patients were younger and had a lower age at diagnosis in comparison to pSS and SSc without CD (p<0.05 for all). Of interest, higher prevalence of CD was detected in SSc patients with diffuse form in comparison to limited SSc (86% vs 14%, p=0.002).
Conclusions:
The results of the present large multicenter study confirm higher prevalence of CD in CTD patients, especially in pSS. Screening of CD may be considered in younger patients with CTD and lower age at diagnosis. The strong association of CD with the diffuse type of SSc is of note and suggests that different, still unexplored, pathogenic mechanisms may characterize the two subsets of the disease. Background: Cardiovascular disease (CVD) is a leading cause of mortality in systemic lupus erythematosus (SLE). Traditional CVD risk scores underperform in SLE. Interestingly, a high prevalence of nonspecific ST-T changes (NST-T) has been recently reported in lupus patients 1,2 . These electrocardiographic findings are known to increase the risk for myocardial infarction, coronary artery disease, CVD, and all-cause mortality 3 in the general population, but in SLE this association remains unknown. Therefore, we sought to define the association of NST-T with the modified Framingham Risk Score (mFRS) as a surrogate outcome for CVD 4 . Objectives: To evaluate if NST-T are associated with higher mFRS in SLE patients without clinical cardiovascular disease. Methods: Adult SLE patients without clinical CVD continuously seen at the Columbia University Lupus Center between April 2016 and January 2017, meeting 1997 American College of Rheumatology classification criteria for SLE were studied. Twelve-lead electrocardiogram (EKG), high sensitivity C-reactive Protein (hsCRP), demographics, disease-specific characteristics, medication use, and CVD risk factors were ascertained. Univariable and multivariable linear regression models were constructed to test the association of NST-T with the mFRS. Results: Seventy-four lupus patients were studied (baseline characteristics in table 1). In univariable analysis, patients with NST-T had a significantly higher mFRS (0.44, p=0.018). There were no confounders identified in the analysis. Background: SLE patients have higher plasma total homocysteine concentrations compared to healthy controls. Hyperhomocysteinemia in SLE is a potentially modifiable, independent risk factor for stroke and thrombotic events, hypertension, and coronary artery calcification. Objectives: We investigated the association of homocysteine levels with the presence of antiphospholipid antibodies as well as the potentially additive thrombotic risk in patients with antiphospholipid antibodies who have hyperhomocysteinemia. Methods: To analyze the association between hyperhomocysteinemia and the presence of antiphospholipid antibodies in SLE, 844 patients with homocysteine measurements were included in the analysis. 237 patients had at least one measurement over 15 umol/L. Patients were followed quarterly after cohort entry. The association of hyperhomocysteinemia with antiphospholipid antibodies is detailed in Table 1 . To analyze the prevalence of vascular events among SLE patients with antiphospholipid antibodies based on homocysteine levels, 571 patients with positive antiphospholipid antibodies and at least one homocysteine measurement were included in the analysis. There were 166 patients with at least one homocysteine measurement over 15 umol/L. The lupus anticoagulant was assessed by dRVVT with mixing studies and confirmatory tests. Anticardiolipin and anti-beta2 glycoprotein 1 were measured by ELISA (INOVA). Vascular events were defined as stroke, myocardial infarction, digital gangrene, and deep vein thrombosis. Results: 
